MedPath

Theophylline

Theophylline Extended-Release Tablets Rx only

Approved
Approval ID

31f3c720-1597-4d43-9296-33017b90b15f

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 11, 2023

Manufacturers
FDA

Alembic Pharmaceuticals Limited

DUNS: 650574663

Products 2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Theophylline

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code46708-026
Application NumberANDA090430
Product Classification
M
Marketing Category
C73584
G
Generic Name
Theophylline
Product Specifications
Route of AdministrationORAL
Effective DateJanuary 11, 2023
FDA Product Classification

INGREDIENTS (5)

HYPROMELLOSE, UNSPECIFIEDInactive
Code: 3NXW29V3WO
Classification: IACT
THEOPHYLLINE ANHYDROUSActive
Quantity: 450 mg in 1 1
Code: 0I55128JYK
Classification: ACTIB
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
POVIDONE K30Inactive
Code: U725QWY32X
Classification: IACT

Theophylline

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code46708-025
Application NumberANDA090430
Product Classification
M
Marketing Category
C73584
G
Generic Name
Theophylline
Product Specifications
Route of AdministrationORAL
Effective DateJanuary 11, 2023
FDA Product Classification

INGREDIENTS (5)

LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
THEOPHYLLINE ANHYDROUSActive
Quantity: 300 mg in 1 1
Code: 0I55128JYK
Classification: ACTIB
HYPROMELLOSE, UNSPECIFIEDInactive
Code: 3NXW29V3WO
Classification: IACT
POVIDONE K30Inactive
Code: U725QWY32X
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Theophylline - FDA Drug Approval Details